Navigation Links
Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
Date:8/27/2013

Oro Valley, AZ (PRWEB) August 27, 2013

Convoy Therapeutics, Inc. has been selected to present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference. The conference will take place on September 18-19, 2013 in Denver, Colorado and is hosted by the Colorado BioScience Association. Convoy Therapeutics is one company among a field of just thirty from Colorado, Arizona, Utah, Montana, and New Mexico that was chosen to present.

Convoy Therapeutics is a subsidiary of ACTUS Biotechnologies, Inc., an accelerator focused on development of novel technologies into commercially available therapies. The Convoy Therapeutics platform technology is based upon a family of peptides, including the proprietary "SPACE" (Skin Penetrating and Cell Entering) peptide. Studies using the peptide in topical formulations with and without covalent attachment have demonstrated an exceptional ability to deliver molecules as large as 1.6 megadaltons past the stratum corneum and into the deeper layers of the skin. Additionally, the technology is capable of creating reservoirs of small molecules, enhancing retention and decreasing dosing frequency, and a demonstrated ability to enhance the penetration of nucleic acids into the skin and cells.

The Convoy Therapeutics platform technology has an enormous range of potential applications in the pharmaceutical, medical aesthetic, cosmetic and vaccine industries, including the opportunity to transform current oral and intravenous drugs into topical formulations for the treatment of dermatological and other diseases.

The company’s lead programs include a topical cosmetic Hyaluronic Acid product for the reduction of fine lines and wrinkles for use between filler or toxin injections, and CycloPsorb™, a topical cyclosporine prescription product for the treatment of psoriasis. The platform is also being investigated with a number of pharmaceutical and cosmetic partners for use with a variety of large and small molecules. Given the challenge that topical macromolecule delivery has posed to the pharmaceutical industry for so many years, the results of the Convoy Therapeutics platform have been remarkable.

For more information on Convoy Therapeutics, visit the company’s website here. For information on ACTUS Biotechnologies, visit the company’s website here. Additional information on the Rocky Mountain Life Science Investor and Partnering Conference can be found here.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11063671.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
2. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
3. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
4. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
5. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
6. Oncology Therapeutics Market in India to 2018 Report
7. PTC Therapeutics Announces Achievement Of Major Milestone In SMA Collaboration
8. NuMe Health Becomes MicroBiome Therapeutics And Recruits New CEO
9. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
10. Sorrento Therapeutics Announces Reverse Split of Common Stock
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):